Olomoucine

Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM). Olomoucine regulates cell cycle and shows anti-melanin tumor activity.


Cat. No.: EX-A12284	Purity: >98%

	Chemical structure of Olomoucine

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	101622-51-9
Purity	>98%
Formula	C15H18N6O
Mol Weight	298.343
Color	White to off-white
State	Solid
Solubility	DMSO : 66.67 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Vesely, J., Havlicek, J., Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994). [2]. Abraham, R.T., Acquarone, M., Andersen, A., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83(2), 105-120 (1995). [3]. Hajdúch M, et al. Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs. 1997 Nov. 8(10):1007-13. [4]. Raynaud FI, et al. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther. 2004 Mar. 3(3):353-62.
CoA	CoA of Olomoucine

Smiles:	OCCNC=1N=C(NCC=2C=CC=CC2)C=3N=CN(C3N1)C


		Search